Autoantibody to PL-12 (Anti-Alanyl-tRNA Synthetase) in an African American Girl with Juvenile Dermatomyositis and Resolution of Interstitial Lung Disease

REFERENCES

1. 1.↵
   1. Feldman BM,
   2. Rider LG,
   3. Reed AM,
   4. Pachman LM

   . Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008;371:2201–12.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Hengstman GJ,
   2. van Engelen BG,
   3. Vree Egberts WT,
   4. van Venrooij WJ

   . Myositis-specific autoantibodies: Overview and recent developments. Curr Opin Rheumatol 2001;13:476–82.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Rider LG,
   2. Miller FW,
   3. Targoff IN,
   4. Sherry DD,
   5. Samayoa E,
   6. Lindahl M,
   7. et al.

   A broadened spectrum of juvenile myositis-specific autoantibodies in children. Arthritis Rheum 1994;37:1534–8.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Christen-Zaechs S,
   2. Seshadri R.,
   3. Sundberg J,
   4. Paller AS,
   5. Pachman LM

   . Juvenile dermatomyositis: Persistent association of nailfold capillaroscopy changes and skin involvement over 36 months with duration of untreated disease. Arthritis Rheum 2008;58:571–6.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Targoff IN,
   2. Arnett FC

   . Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med 1990;88:241–51.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Pachman LM,
   2. Geraci N,
   3. Morgan G,
   4. Daniels B,
   5. Seshadri R,
   6. Sullivan D,
   7. et al.

   Absolute number of circulating CD3-CD56+/CD16+ natural killer (NK) cells, a potential biomarker of disease activity in juvenile dermatomyositis (JDM) [abstract]. Arthritis Rheum 2008;58 Suppl:S225.

   OpenUrl
7. 7.↵
   1. Rouster-Stevens KA,
   2. Gursahaney A,
   3. Ngai K-L,
   4. Daru JA,
   5. Pachman LM

   . Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Care Res 2008;59:222–66.

   OpenUrlCrossRef
8. 8.↵
   1. Rouster-Stevens KA,
   2. Morgan GA,
   3. Wang D,
   4. Pachman LM

   . Mycophenolate mofetil, a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res 2010;62:1446–51.

   OpenUrlCrossRef
9. 9.↵
   1. Love LA,
   2. Leff RL,
   3. Fraser DD,
   4. Targoff IN,
   5. Dalakas M,
   6. Plotz PH,
   7. et al.

   A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70:360–74.

   OpenUrlPubMed
10. 10.↵
    1. Kalluri M,
    2. Sahn SA,
    3. Oddis CV,
    4. Gharib SL,
    5. Christopher-Stine L,
    6. Danoff SK,
    7. et al.

    Clinical profile of anti-PL-12 autoantibody: Cohort study and review of the literature. Chest 2009;135:1550–6.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Pachman LM,
    2. Cooke N

    . Juvenile dermatomyositis: A clinical and immunological study. J Pediatr 1980;96:226–34.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Huber AM,
    2. Feldman BM,
    3. Rennebohm RM,
    4. Hicks JE,
    5. Lindsley CB,
    6. Perez MD,
    7. et al.

    Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004;50:1595–603.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Guzman J,
    2. Petty RE,
    3. Malleson PN

    . Monitoring disease activity in juvenile dermatomyositis: The role of von Willebrand factor and muscle enzymes. J Rheumatol 1994;21:739–43.

    OpenUrlPubMed
14. 14.↵
    1. Ansell BA,
    2. Miller JJ III.,
    3. Pachman LM,
    4. Sullivan DB

    . Controversies in juvenile dermatomyositis. J Rheumatol 1990;17:1–6.

    OpenUrlCrossRefPubMed